Pennsylvania has sued Character.AI, alleging its chatbots falsely posed as licensed mental health professionals, including one bot impersonating a psychiatrist that provided a fabricated state license number.
CareMother, built by Doto Health with UNICEF Femtech Ventures support, uses AI to automate labor monitoring, partograph charting and cardiotocography interpretation in Indian maternity wards, aiming to catch preventable complications in real time.
The 2026 NCCN breast cancer screening guidelines now incorporate AI-derived risk scores from standard mammograms, using a 5-year risk threshold of 1.7 percent to trigger shared decisions about additional screening like MRI.
An estimated 50 million women worldwide use period-tracking apps that increasingly rely on AI to generate predictions, and a Vrije Universiteit Amsterdam event this month is examining the privacy and accountability gaps that come with it.
An IAPP privacy analysis of five health-focused AI agents launched within three months found each promises not to train on users' health data and keeps health chats isolated from ordinary conversations, but verification of those promises remains out of reach for outside researchers.
OpenAI's January 7, 2026 launch of ChatGPT Health lets users link medical records and wellness apps to the chatbot, with what the company describes as purpose-built encryption and isolation designed specifically for health conversations.
A Kentucky federal lawsuit, Barrows et al. v. Humana, accusing the insurer of using AI tools to improperly terminate post-acute care coverage for Medicare Advantage patients, received a scheduling order in July 2026 and remains actively litigated.
A federal judge in Minnesota has ordered UnitedHealth to produce internal documents about its nH Predict algorithm, used to deny rehabilitation care to Medicare Advantage patients, after a lawsuit alleged the tool had a 90 percent error rate on appeal.
ArteraAI Breast has become the first FDA-cleared AI digital-pathology risk test for breast cancer, giving doctors a new way to estimate how aggressively a tumor is likely to behave directly from pathology images.
The FDA has cleared Tempus's AI-driven xT CDx, a tumor-profiling diagnostic that helps oncologists match cancer patients to targeted therapies based on their tumor's genetic signature.